Skip to content
Evigrade
MinorTestosterone 5α-reductase types 1 and 2 inhibitors×Bile acid preparations

Updated · Methodology

Mechanism

Ursodeoxycholic acid is absorbed in the small intestine, conjugated with glycine or taurine in the liver and secreted into bile (ursodeoxycholic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dutasteride is metabolised by CYP3A4 and CYP3A5 and is excreted mainly in the faeces as metabolites (dutasteride SmPC, AEMPS). According to the ursodeoxycholic acid SmPC, observations with nitrendipine and dapsone might indicate that it induces CYP3A enzymes. However, a well-designed interaction study with budesonide, a known CYP3A substrate, found no induction (ursodeoxycholic acid SmPC, AEMPS). The dutasteride documents mention no CYP3A4 inducers, and neither colestyramine, which binds bile acids, nor food affected dutasteride absorption (dutasteride SmPC, AEMPS, and Avodart label, US Food and Drug Administration, FDA). No document names the pair.

Symptoms

The documents describe no symptoms of this combination. A common adverse effect of ursodeoxycholic acid is pasty stools or diarrhoea (ursodeoxycholic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and the US label lists alopecia among its most common adverse reactions (URSO label, US Food and Drug Administration, FDA). The most common adverse effects of dutasteride are impotence, decreased libido, ejaculation disorders and breast disorders. Hair loss, mainly of body hair, and excess hair growth are uncommon (dutasteride SmPC, AEMPS).

Management

According to the documents, the combination is acceptable, and the doses of ursodeoxycholic acid and dutasteride need no change. No document names the pair, and a study with a CYP3A substrate found no CYP3A induction by ursodeoxycholic acid (ursodeoxycholic acid SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and URSO label, US Food and Drug Administration, FDA; dutasteride SmPC, AEMPS, and Avodart label, FDA). Ursodeoxycholic acid is used, among other indications, for primary biliary cholangitis. Dutasteride is contraindicated in severe hepatic impairment and is used with caution in mild to moderate hepatic impairment (ursodeoxycholic acid and dutasteride SmPCs, AEMPS). During the first 3 months of ursodeoxycholic acid treatment, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) are checked every 4 weeks, and every 3 months after that (ursodeoxycholic acid SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dutasteride

Other interactions with Ursodeoxycholic acid